Tag: partly
The New Xbox Wireless Controller – Remix Special Edition Is Made Partly from Reclaimed CDs, Water Jugs… and Other Controllers’ Parts
The atmospheric ‘seesaw’ partly responsible for this week’s cold snap
MSG Entertainment partly lifts its venue ban on attorneys involved in suing the company
Michael Gove admits bad government guidance was partly responsible for the Grenfell tragedy
MICHAEL Gove has admitted bad government guidance was partly responsible for the Grenfell tragedy.
Seventy two people died when fire engulfed the tower block in 2017.
Grenfell Tower was covered in flammable panels, leading to the rapid spread of the blaze[/caption]
The Housing Secretary admitted the failure ahead of the findings of the public inquiry into the West London blaze, due out later this year.
Mr Gove said he expected the probe to point the finger of blame at the Government, developers and cladding firms.
He also said he is “deeply sorry” to homeowners who were stuck in flats with unsafe cladding after developers dragged their feet about tackling the problem.
Mr Gove told The Sunday Times guidance on building materials “allowed unscrupulous people to exploit a broken system in a way that led to tragedy”.
He also suggested cladding firms showed “an active willingness to put people in danger in order to make a profit”.
Grenfell Tower was covered in flammable panels.
In the wake of the disaster, leaseholders in up to 1.5million flats with unsafe cladding were unable to sell.
Mr Gove will tomorrow say developers who signed up to a voluntary £2billion pledge to alter their buildings will be slapped with binding contracts.
Ex-Rocket Lab engineer raises $21M for Partly to make buying car parts easier
Car parts buyers require specific parts to fit specific vehicles, making for a supply-constrained environment. New Zealand-based Partly wants to ease those constraints by connecting parts buyers around the world with the correct parts. The two-year-old startup is not a car parts marketplace. Rather, Partly powers marketplaces like eBay and Shopify with its database of […]
Ex-Rocket Lab engineer raises $21M for Partly to make buying car parts easier by Rebecca Bellan originally published on TechCrunch
FDA Approves ALS Drug Whose Study Was Partly Funded By Ice Bucket Challenge
In November, Amylyx submitted a drug application to the FDA for the medication, then called AMX0035, as an oral ALS treatment, seeking approval based on a Phase 2 trial that included 137 people with ALS who received either the drug or a placebo for 24 weeks. The study was funded in part by a grant from the ALS Ice Bucket Challenge, the viral social media campaign that started in 2014 involving people dumping buckets of ice water over themselves to raise awareness and money around ALS. The trial also showed that the drug was generally well-tolerated, but there was a greater frequency of gastrointestinal events in the group getting the medication. Amylyx is now continuing to study its safety and efficacy in a Phase 3 trial. In March, the Peripheral and Central Nervous System Drugs Advisory Committee voted 6-4 that a single Phase 2 trial did not establish the conclusion that the drug is effective in treating ALS.
One key difference between the FDA advisory committee’s March and September meetings is that in the later meeting, Amylyx indicated that if the drug was approved but its Phase 3 trial results fail to confirm the drug’s benefits, the company would consider withdrawing the drug from the market, Lynch said. She added, however, that the company didn’t say specifically what it would view as a failure. “So at the vote, the advisory committee members switched, and most of them said, ‘Yes, we are now convinced that this product should be approved.’ And when they were asked why they changed their minds, some of them said, ‘Well, the company said they would withdraw,'” she said. “And they were also convinced by patients’ testimonies that they very much want to try this drug.” But overall, the FDA’s approval was based on Phase 2 trial data, which, Lynch said, may send a message to other pharmaceutical companies that they don’t need robust Phase 3 trial data to get products on the market. Although people with ALS want access to this promising drug, there are concerns that such a message could open the door more broadly to the approval of medications that have not been proved to work, says Holly Fernandez Lynch, an assistant professor of medical ethics and health policy at the University of Pennsylvania. “The FDA could later withdraw those products if needed, she said, but doing so without voluntary company agreement is ‘a huge pain’ and often requires a very lengthy process,” reports CNN.
Read more of this story at Slashdot.